Drug Profile
Tesofensine - Saniona
Alternative Names: NS-2330; TesofensineLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator NeuroSearch
- Developer Medix; Saniona
- Class Antidementias; Antiparkinsonians; Chlorobenzenes; Heterocyclic bicyclo compounds; Neuroprotectants; Nootropics; Obesity therapies; Small molecules
- Mechanism of Action Biogenic monoamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Obesity
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Obesity(In volunteers) in Germany (PO, Tablet)
- 25 Jun 2021 Seniona and Medix anticipates approval of tesofensine for Obesity in Mexico in 2022
- 28 Aug 2020 Seniona plans a phase III trial in Obesity in first half of 2021